These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39095649)

  • 21. Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial.
    Hannoun-Levi JM; Chand-Fouche ME; Pace-Loscos T; Gautier M; Gal J; Schiappa R; Pujol N
    Clin Transl Radiat Oncol; 2022 Nov; 37():64-70. PubMed ID: 36093342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients.
    Marina O; Gustafson GS; Kestin LL; Brabbins DS; Chen PY; Ye H; Martinez AA; Ghilezan MI; Wallace M; Krauss DJ
    Brachytherapy; 2014; 13(1):59-67. PubMed ID: 23871661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved rectal dosimetry with the use of SpaceOAR during high-dose-rate brachytherapy.
    Wu SY; Boreta L; Wu A; Cheung JP; Cunha JAM; Shinohara K; Chang AJ
    Brachytherapy; 2018; 17(2):259-264. PubMed ID: 29203149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
    Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
    Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
    Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
    Parzen JS; Ye H; Gustafson G; Yan D; Martinez A; Chen PY; Ghilezan M; Sebastian E; Limbacher A; Krauss DJ
    Radiother Oncol; 2020 Jun; 147():123-129. PubMed ID: 32276193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
    Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
    Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3D interstitial HDR brachytherapy combined with 3D external beam radiotherapy and androgen deprivation for prostate cancer. Preliminary results.
    Martin T; Hey-Koch S; Strassmann G; Kolotas C; Baltas D; Rogge B; Röddiger S; Vogt HG; Heyd R; Dannenberg T; Kurek R; Tunn U; Zamboglou N
    Strahlenther Onkol; 2000 Aug; 176(8):361-7. PubMed ID: 10987019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer.
    Kestin LL; Martinez AA; Stromberg JS; Edmundson GK; Gustafson GS; Brabbins DS; Chen PY; Vicini FA
    J Clin Oncol; 2000 Aug; 18(15):2869-80. PubMed ID: 10920135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer.
    Soumarová R; Homola L; Stursa M; Perková H
    Neoplasma; 2006; 53(5):410-7. PubMed ID: 17013535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Prospective Study of Magnetic Resonance Imaging-guided Focal Salvage High-dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients.
    Corkum MT; Morton G; Loblaw DA; Tseng CL; Murgic J; Ravi A; Davidson MTM; Wronski M; Haider M; Chung HT
    Pract Radiat Oncol; 2022; 12(6):e531-e537. PubMed ID: 35718075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience.
    Jabbari S; Hsu IC; Kawakami J; Weinberg VK; Speight JL; Gottschalk AR; Roach M; Shinohara K
    Brachytherapy; 2009; 8(4):339-44. PubMed ID: 19428310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786).
    Vigneault E; Morton G; Parulekar WR; Niazi TM; Springer CW; Barkati M; Chung P; Koll W; Kamran A; Monreal M; Ding K; Loblaw A
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):527-533. PubMed ID: 29903505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
    Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
    Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
    Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort.
    Marotte D; Gal J; Schiappa R; Gautier M; Boulahssass R; Chand-Fouche ME; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2022 Jul; 35():104-109. PubMed ID: 35692263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: Results of a prospective study.
    Vigneault E; Mbodji K; Racine LG; Chevrette E; Lavallée MC; Martin AG; Després P; Beaulieu L
    Brachytherapy; 2016; 15(6):746-751. PubMed ID: 27743955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.